AU1110099A - Method of reducing craving in mammals - Google Patents

Method of reducing craving in mammals Download PDF

Info

Publication number
AU1110099A
AU1110099A AU11100/99A AU1110099A AU1110099A AU 1110099 A AU1110099 A AU 1110099A AU 11100/99 A AU11100/99 A AU 11100/99A AU 1110099 A AU1110099 A AU 1110099A AU 1110099 A AU1110099 A AU 1110099A
Authority
AU
Australia
Prior art keywords
antagonist
cocaine
sch
food
agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU11100/99A
Other languages
English (en)
Inventor
Vicki Coffin
Paul W. Glue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU1110099A publication Critical patent/AU1110099A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU11100/99A 1997-10-28 1998-10-26 Method of reducing craving in mammals Abandoned AU1110099A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95921397A 1997-10-28 1997-10-28
US08959213 1997-10-28
PCT/US1998/022255 WO1999021540A2 (en) 1997-10-28 1998-10-26 Method of reducing craving in mammals

Publications (1)

Publication Number Publication Date
AU1110099A true AU1110099A (en) 1999-05-17

Family

ID=25501785

Family Applications (1)

Application Number Title Priority Date Filing Date
AU11100/99A Abandoned AU1110099A (en) 1997-10-28 1998-10-26 Method of reducing craving in mammals

Country Status (16)

Country Link
EP (1) EP1043980A2 (pt)
JP (1) JP2001520989A (pt)
KR (1) KR20010031470A (pt)
CN (1) CN1283116A (pt)
AR (1) AR015984A1 (pt)
AU (1) AU1110099A (pt)
BR (1) BR9814830A (pt)
CA (1) CA2308453A1 (pt)
CO (1) CO4970824A1 (pt)
HU (1) HUP0100115A2 (pt)
IL (1) IL135659A0 (pt)
NO (1) NO20002149L (pt)
PE (1) PE122299A1 (pt)
SK (1) SK5812000A3 (pt)
WO (1) WO1999021540A2 (pt)
ZA (1) ZA989786B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9908392A (pt) * 1998-03-02 2000-10-31 Schering Corp Uso de antagonistas de d1/d5 para o tratamento de distúrbios obsessivos compulsivos, distúrbios somatofórmicos, distúrbios dissociativos, distúrbios de alimentação, distúrbios de controle de impulsos e autismo
US6410527B1 (en) * 1998-03-02 2002-06-25 Schering Corporation Method of treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders, and autism
US6541520B1 (en) 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
US6890951B2 (en) 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US6395783B1 (en) 2000-10-23 2002-05-28 Brookhaven Science Associates, Llc Treatment of PCP addiction and PCP addiction-related behavior
US6462084B1 (en) 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
EP1441708B1 (en) 2001-11-05 2009-04-08 Krele Pharmaceuticals LLC Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
WO2012050594A1 (en) 2010-09-01 2012-04-19 Tonix Pharmaceuticals, Inc. Treatment for cocaine addiction
PL2872145T3 (pl) 2012-07-12 2022-06-20 Emalex Biosciences, Inc. Połączone benzazepiny w leczeniu zespołu tourette’a
LT3057595T (lt) 2013-10-18 2020-08-10 Emalex Biosciences, Inc. Sintezuoti benzazepinai, skirti mikčiojimui gydyti
CN110327350B (zh) * 2019-07-11 2021-02-23 温州医科大学 多巴胺d1受体拮抗剂sch39166在作为制备治疗眼部病理性血管新生药物的应用
CN110833621A (zh) * 2019-12-06 2020-02-25 中国医科大学 多巴胺受体1拮抗剂在制备治疗对氯胺酮致小鼠类精神分裂症药物上的应用
US12594281B2 (en) 2024-03-15 2026-04-07 Emalex Biosciences, Inc. Pharmaceutical dosage forms and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607967A (en) * 1994-10-27 1997-03-04 Merck & Co., Inc. Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid
AU3408097A (en) * 1996-06-06 1998-01-05 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and seroto nin agonists

Also Published As

Publication number Publication date
SK5812000A3 (en) 2000-12-11
JP2001520989A (ja) 2001-11-06
CO4970824A1 (es) 2000-11-07
CA2308453A1 (en) 1999-05-06
WO1999021540A3 (en) 1999-09-02
IL135659A0 (en) 2001-05-20
WO1999021540B1 (en) 1999-10-28
EP1043980A2 (en) 2000-10-18
NO20002149D0 (no) 2000-04-27
CN1283116A (zh) 2001-02-07
HUP0100115A2 (hu) 2001-06-28
ZA989786B (en) 1999-04-28
KR20010031470A (ko) 2001-04-16
AR015984A1 (es) 2001-05-30
PE122299A1 (es) 1999-12-04
NO20002149L (no) 2000-06-26
BR9814830A (pt) 2000-10-03
WO1999021540A2 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
US6262049B1 (en) Method of reducing nicotine and tobacco craving in mammals
Davies et al. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology
Miceli et al. Single‐and multiple‐dose pharmacokinetics of ziprasidone under non‐fasting conditions in healthy male volunteers
US8729070B2 (en) CNS pharmaceutical compositions and methods of use
US9579299B2 (en) CNS pharmaceutical compositions and methods of use
AU1110099A (en) Method of reducing craving in mammals
US20050038062A1 (en) Methods and materials for the treatment of pain comprising opioid antagonists
PL201685B1 (pl) Zastosowanie N-piperydyno-5-(4-chlorofenylo)-1-(2,4-dichlorofenylo)-4-metylopirazolo-3-karboksyamidu do wytwarzania leków
CA2250042A1 (en) Treating pain using a synergistic combination of an atypical antipsychotic and a drug used in treatment of pain
CA2263163A1 (en) Treatment of upper airway allergic responses with a combination of histamine receptor antagonists
AU740504B2 (en) Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, motion sickness and vertigo
WO1995007690A1 (en) Composition and method for treating nicotine craving in smoking cessation
KR20060100443A (ko) 이상지혈증의 예방과 치료, 및 이상지혈증 및(또는) 비만과관련된 질환의 예방과 치료를 위한 약제의 제조에있어서의 피라졸 유도체의 용도
WO1989005642A1 (en) Dextrorphan potentiator for anticonvulsant composition and method
EP2138174A1 (en) Pharmaceutical composition in the form of a sublingual tablet consisting of a non-steroidal anti-inflammatory agent and an opiate analgesic for pain management
US4898860A (en) Anticonvulsant composition and method
AU629688B2 (en) Slowly dissociating (tight binding) dopamine, serotonin or norepinephrine reuptake inhibitors as cocaine, amphetamine and phencyclidine antagonists
WO2016027259A1 (en) Cns pharmaceutical compositions and methods of use
MXPA00004135A (en) Method of reducing craving in mammals
Chappell et al. Zatosetron, a 5-HT3 receptor antagonist in a multicenter trial for acute migraine
KR102253526B1 (ko) 여성 성 기능이상에 대한 브레멜라노타이드 요법
CZ20001387A3 (cs) Použití antagonisty a jeho sestava
Glasser et al. Safety and efficacy of monotherapy with fantofarone, a novel calcium channel antagonist, in patients with chronic stable angina pectoris
EP1200093A2 (en) Use of 2-amino-4-(4-fluoronaphth-1-yl)-6-isopropylpyrimidine in the treatment of gi disorders
Knapp et al. Clinical Experience with the NMDA Ion Channel Blocker, Aptiganel Hydrochloride (CERESTAT®)

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted